Sudarshan Hebbar Biography and Net Worth

Chief Medical Officer of CalciMedica

Dr. Hebbar has more than 15 years of clinical development and product-development experience across therapeutics and diagnostics, following 12 years in clinical practice in nephrology, hypertension, transplantation, and critical care. His industry experience includes Reata Pharmaceuticals, Abbott, Thrasos Innovation, and Oncimmune.

What is Sudarshan Hebbar's net worth?: The estimated net worth of Sudarshan Hebbar is at least $18.34 thousand as of August 19th, 2025. Dr. Hebbar owns 12,307 shares of CalciMedica stock worth more than $18,337 as of October 7th. This net worth approximation does not reflect any other investments that Dr. Hebbar may own. Learn More about Sudarshan Hebbar's net worth.
How do I contact Sudarshan Hebbar?: The corporate mailing address for Dr. Hebbar and other CalciMedica executives is 505 Coast Boulevard South, Suite 307, LA Jolla, CA, 92037. CalciMedica can also be reached via phone at 858-952-5500 and via email at [email protected]. Learn More on Sudarshan Hebbar's contact information.
Has Sudarshan Hebbar been buying or selling shares of CalciMedica?: Sudarshan Hebbar has not been actively trading shares of CalciMedica within the last three months. Most recently, on Tuesday, August 19th, Sudarshan Hebbar bought 1,912 shares of CalciMedica stock. The stock was acquired at an average cost of $14.10 per share, with a total value of $26,959.20. Following the completion of the transaction, the insider now directly owns 12,307 shares of the company's stock, valued at $173,528.70. Learn More on Sudarshan Hebbar's trading history.
Who are CalciMedica's active insiders?: CalciMedica's insider roster includes Stephen Bardin (CFO), Sudarshan Hebbar (Chief Medical Officer), A. Leheny (CEO), Eric Roberts (Insider), and Kenneth Stauderman (Chief Scientific Officer). Learn More on CalciMedica's active insiders.
Are insiders buying or selling shares of CalciMedica?: In the last twelve months, CalciMedica insiders bought shares 1 times. They purchased a total of 49,794 shares worth more than $199,176.00. The most recent insider tranaction occured on June, 25th when Director Fred A Middleton bought 49,794 shares worth more than $199,176.00. Insiders at CalciMedica own 28.3% of the company. Learn More about insider trades at CalciMedica.
Information on this page was last updated on 6/25/2026.

Sudarshan Hebbar Insider Trading History at CalciMedica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2025	Buy	1,912	$14.10	$26,959.20	12,307
8/15/2025	Buy	878	$13.95	$12,248.10	10,395
8/14/2025	Buy	316	$12.90	$4,076.40	9,516

Sudarshan Hebbar Buying and Selling Activity at CalciMedica

CalciMedica Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.47

$1.49

50 Day Range

MA: $2.55

$1.49

$5.00

2 Week Range

Now: $1.47

$1.42

$36.00

Volume

315 shs

Average Volume

187,891 shs

Market Capitalization

$10.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76